Health
Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class
With a mean weight loss of 16.6%1, Wegovy® pill demonstrates best-in-class weight-loss efficacy and is the first oral GLP-1 treatment recommended by CHMP for weight management in the EU.CHMP recommends Wegovy® pill for approval to reduce excess body weight and maintain long-term weight reduction. The recommendation also includes data from SELECT which demonstrates that Wegovy® reduces the risk of major adverse cardiovascular events (MACE)*, in the label.Wegovy® pill is the only oral GLP-1 treatm
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GU8RSeYXqJzkiM2VxLxQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMA--/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/GU8RSeYXqJzkiM2VxLxQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMA--/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"With a mean weight loss of 16.6%1, Wegovy® pill demonstrates best-in-class weight-loss efficacy and is the first oral GLP-1 treatment recommended by CHMP for weight management in the EU.","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"CHMP recommends Wegovy® pill for approval to reduce excess body weight and maintain long-term weight reduction. The recommendation also includes data from SELECT which demonstrates that Wegovy® reduces the risk of major adverse cardiovascular events (MACE)*, in the label.","length":272,"tagName":"p"}]},{"val":[{"type":"text","content":"Wegovy® pill is the only oral GLP-1 treatment with no drug-drug restrictions in the label.","length":90,"tagName":"p"}]},{"val":[{"type":"text","content":"Novo Nordisk plans to launch Wegovy® pill in select markets outside the US in the second half of 2026.","length":102,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":650,"olType":false},{"type":"text","content":"Bagsværd, Denmark, 22 May 2026 – Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation of Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain long-term weight reduction. The positive opinion also includes SELECT data in the label, demonstrating that Wegovy® reduces the risk of major adverse cardiovascular events (MACE)*.","length":510,"tagName":"p"},{"type":"text","content":"Wegovy® pill is the first oral glucagon-like peptide-1 (GLP-1...